First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and ...

Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion ...

Addressing a CII India Reception on the sidelines of the SelectUSA Investment Summit at National Harbour in Maryland on Monday evening, May 4, US Deputy Undersecretary (Policy and International Trade ...

Organon & Co. recently released its 10-Q report. Organon is a global healthcare company focused on women’s health and general ...

On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

Post-Organon deal, ICICI Direct downgraded Sun Pharma to Hold, IIFL adjusted to Add, Investec maintained a Sell rating, while ...

Geopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for ...

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 ...

Shares of Organon & Co surged on Friday after a report that Sun Pharma ceutical Industries plans to increase its binding offer for the women’s healthcare company to $13 billion.

Sun Pharma’s acquisition of US-based Organon looks like a financial bargain for the global scale and market access it offers. But the Indian drugmaker may need to look elsewhere for an R&D boost that ...

Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to ...